Genetically engineered microorganisms are also producing the enzyme urokinase, used to dissolve blood clots; the hormone thymosin alpha1, which shows promise as a treatment for .
In 1979 the company developed thymosin alpha1, which is now being tested by the National Cancer Institute for possible treatment of certain types of brain and lung cancer.
RegeneRx Receives Orphan Drug Designation for T?4 in the Treatment of Neurotrophic Keratopathy RegeneRx Biopharmaceuticals, Inc. announced that it has received Orphan Drug designation from U.S. FDA’s Office of Orphan Products Development for its drug candidate, Thymosin beta 4 , for the treatment of Neurotrophic Keratopathy , a serious degenerative disease of the corneal epithelium .
Jan. 3, 2014 - Business Wire via Yahoo! Finance